| Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs A Bindoli, MP Rigobello, G Scutari, C Gabbiani, A Casini, L Messori Coordination Chemistry Reviews 253 (11-12), 1692-1707, 2009 | 607 | 2009 |
| Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies S Nobili, E Mini, I Landini, C Gabbiani, A Casini, L Messori Medicinal research reviews 30 (3), 550-580, 2010 | 533 | 2010 |
| Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium (II)− arene compounds A Casini, C Gabbiani, F Sorrentino, MP Rigobello, A Bindoli, TJ Geldbach, ... Journal of medicinal chemistry 51 (21), 6773-6781, 2008 | 324 | 2008 |
| Gold (III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ... Journal of inorganic biochemistry 102 (3), 564-575, 2008 | 302 | 2008 |
| Nanoparticles of Mg(OH)2: Synthesis and Application to Paper Conservation R Giorgi, C Bozzi, L Dei, C Gabbiani, BW Ninham, P Baglioni Langmuir 21 (18), 8495-8501, 2005 | 261 | 2005 |
| Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives M Navarro, C Gabbiani, L Messori, D Gambino Drug discovery today 15 (23-24), 1070-1078, 2010 | 252 | 2010 |
| Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold (III) compounds with bipyridyl ligands A Casini, MA Cinellu, G Minghetti, C Gabbiani, M Coronnello, E Mini, ... Journal of Medicinal Chemistry 49 (18), 5524-5531, 2006 | 229 | 2006 |
| Aluminum, copper, iron and zinc differentially alter amyloid-Aβ1–42 aggregation and toxicity S Bolognin, L Messori, D Drago, C Gabbiani, L Cendron, P Zatta The international journal of biochemistry & cell biology 43 (6), 877-885, 2011 | 181 | 2011 |
| New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications AR Sannella, A Casini, C Gabbiani, L Messori, AR Bilia, FF Vincieri, ... FEBS letters 582 (6), 844-847, 2008 | 178 | 2008 |
| Gold (III) compounds as anticancer drugs C Gabbiani, A Casini, L Messori Gold Bulletin 40, 73-81, 2007 | 176 | 2007 |
| Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold (III) compounds for cancer treatment: a systematic study A Casini, G Kelter, C Gabbiani, MA Cinellu, G Minghetti, D Fregona, ... JBIC Journal of Biological Inorganic Chemistry 14, 1139-1149, 2009 | 155 | 2009 |
| Mechanisms of cytotoxicity of selected organogold (III) compounds M Coronnello, E Mini, B Caciagli, MA Cinellu, A Bindoli, C Gabbiani, ... Journal of medicinal chemistry 48 (21), 6761-6765, 2005 | 150 | 2005 |
| Clioquinol decreases amyloid-β burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease C Grossi, S Francese, A Casini, MC Rosi, I Luccarini, A Fiorentini, ... Journal of Alzheimer's disease 17 (2), 423-440, 2009 | 132 | 2009 |
| Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound A Casini, C Gabbiani, E Michelucci, G Pieraccini, G Moneti, PJ Dyson, ... JBIC Journal of Biological Inorganic Chemistry 14, 761-770, 2009 | 126 | 2009 |
| Structural characterization, solution studies, and DFT calculations on a series of binuclear gold (III) oxo complexes: relationships to biological properties C Gabbiani, A Casini, L Messori, A Guerri, MA Cinellu, G Minghetti, ... Inorganic chemistry 47 (7), 2368-2379, 2008 | 116 | 2008 |
| ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium (II)‐Arene PTA (RAPTA) Complexes A Casini, G Mastrobuoni, WH Ang, C Gabbiani, G Pieraccini, G Moneti, ... ChemMedChem: Chemistry Enabling Drug Discovery 2 (5), 631-635, 2007 | 107 | 2007 |
| ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme A Casini, G Mastrobuoni, C Temperini, C Gabbiani, S Francese, G Moneti, ... Chemical communications, 156-158, 2006 | 103 | 2006 |
| Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold (III) compounds studied with combined mass spectrometry and … C Gabbiani, G Mastrobuoni, F Sorrentino, B Dani, MP Rigobello, A Bindoli, ... MedChemComm 2 (1), 50-54, 2011 | 100 | 2011 |
| Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c A Casini, C Gabbiani, G Mastrobuoni, L Messori, G Moneti, G Pieraccini ChemMedChem: Chemistry Enabling Drug Discovery 1 (4), 413-417, 2006 | 99 | 2006 |
| Trace copper (II) or zinc (II) ions drastically modify the aggregation behavior of amyloid-β 1–42: An AFM study M Innocenti, E Salvietti, M Guidotti, A Casini, S Bellandi, ML Foresti, ... Journal of Alzheimer's Disease 19 (4), 1323-1329, 2010 | 93 | 2010 |
Federica Scaletti, PhDBloom Bioscience在 bloombioscience.com 的电子邮件经过验证
